Dr. Heidi Overton, President Trump's pick to lead the Food and Drug Administration (FDA), spent her Thursday confirmation hearing demonstrating a rare political skill: saying words without committing to any of them. The Senate Health, Education, Labor and Pensions (HELP) Committee hearing revealed plenty about what senators care about and almost nothing about how Overton would run the agency responsible for drugs, tobacco, vaccines, and much of the food supply.
Overton did voice support for established vaccines, which put her at odds with Trump's previous description of the measles, mumps and rubella (MMR) vaccine as "lethal." Under questioning from HELP Committee chairman Sen. Bill Cassidy (R-La.), she confirmed that "every vaccine on the market right now are safe and effective," MMR included, and called it the best public health tool to address the ongoing measles outbreak. Cassidy, a physician, had said Overton needed to repudiate Trump's comments to earn his vote. She would not directly say Trump was wrong, nor would she commit to standing up to the president or Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.
Cassidy, who has a habit of extracting promises from health nominees that later evaporate, noted that Kennedy had given him guarantees and then backtracked. "If the President asks you to do something that goes against those guarantees you give us today, what will you do?" he asked. Overton said she would "follow the statutory requirements" for FDA commissioners and give Trump her best advice - a response that answered the question in the same way a fortune cookie answers a yes-or-no question.
Cassidy hasn't said whether he'll vote to confirm Overton, though he has voted for every other HHS nominee who came before his committee despite his stated concerns. Overton needs every Republican on the panel if all Democrats oppose her.
Overton currently serves as a top domestic policy adviser at the White House and previously worked as chief policy adviser at a conservative think tank. She worked on various administration health initiatives, including an executive order to reduce the number of recommended childhood vaccines - an order she called "historic" while standing beside Trump in the Oval Office as he falsely claimed the combined MMR shot could be "quite lethal."
Later, Sen. Maggie Hassan (D-N.H.) pressed Overton on Trump's comments that Tylenol can cause autism if taken by pregnant women. "I haven't seen any casual evidence that Tylenol causes autism," Overton said, but she wouldn't say Trump was wrong when he told pregnant women not to take it. "I'm really concerned that if an FDA commissioner will not tell the American public that the president is wrong about something, that poses a real threat to our health," Hassan said.
Trump himself weighed in via Truth Social last month: "Dr. Heidi has been a ROCKSTAR in my Administration, where she has worked directly with Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History."
If confirmed, Overton would inherit an agency roiled by an exodus of top staff and viewed by many in the healthcare industry as less trustworthy and more politicized than in any previous administration. She'll face the same headwinds that plagued her predecessor, Marty Makary: political interference, funding cuts, and balancing the demands of the "Make America Healthy Again" (MAHA) movement against the MAGA White House. She would also take on controversial initiatives including a safety review of the abortion pill mifepristone and new FDA rules making it easier for companies to market flavored electronic cigarettes even without approval.
On mifepristone, Overton wouldn't directly say whether she believes it's safe, despite questions from numerous Democrats. Overton is openly anti-abortion and has described the 2022 Supreme Court ruling overturning Roe v. Wade as "a huge victory for life." Sen. Patty Murray (D-Wash.) brought up a 2023 policy paper Overton wrote while at the Trump-aligned America First Policy Institute, in which she argued "chemical abortions pose serious risks to women" and warned against allowing "abortion on demand" through telehealth prescribing of mifepristone. Overton told Murray the pill "has met the safety and efficacy determinations of the FDA" and said she didn't want to "prejudge" the ongoing safety review, which abortion rights advocates condemn as politically driven. Initial results are expected within weeks.
Overton's mifepristone views could complicate her support among moderate Republicans. Sen. Lisa Murkowski (R-Alaska), who supports abortion rights, expressed concern that the review is politically pressured. "This is a drug that is FDA approved, has been in use for well over two decades now," Murkowski said, adding her state would be in a "very challenging position" if in-person dispensing requirements were reinstated. But Murkowski said she didn't bother asking Overton about it, expecting only "the exact same very specific technical responses" she'd given everyone else.
Overton will also likely need to win over Sen. Susan Collins (R-Maine), the other pro-abortion rights Republican on the panel, who faces a tough reelection campaign where abortion is a top issue. Collins instead focused her questions on flavored electronic cigarettes and the administration's efforts to dismantle guardrails limiting tobacco industry growth. She said she worries recent approvals of fruit-flavored vaping products will jeopardize progress in reducing youth e-cigarette use. Overton said the administration agrees about protecting kids from flavored vapes but noted the approvals had backing from FDA scientists because the products helped adult smokers quit cigarettes.